{'fraction_non_alphanumeric': 0.01866251944012442, 'fraction_numerical': 0.0, 'mean_word_length': 6.402298850574713, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury.

Early clinical trials of glucose-insulin-potassium for acute myocardial infarction were inconclusive. However, several recent placebo-controlled, prospective, randomized clinical trials of glucose-insulin-potassium for acute myocardial infarction or metabolic support during and after cardiac surgery have demonstrated its efficacy. These clinical results are supported by experimental studies that have shown a strong protective effect of increased glycolytic substrate on ischemic myocardium in concert with an improved bioenergetic status.